Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors

2008 ◽  
Vol 28 (8) ◽  
pp. 951-959 ◽  
Author(s):  
James A Kaye ◽  
Hershel Jick
Keyword(s):  
Risk Factors ◽  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Hip Fractures

scholarly journals Risk factors of incomplete response to proton pump inhibitor therapy in patients with mild erosive esophagitis

2014 ◽  
Vol 2 (1) ◽  
pp. 18-24
Author(s):  
Sung-Shuo Kao ◽  
Deng-Chyang Wu ◽  
Seng-Kee Chuah ◽  
Chao-Hung Kuo ◽  
Ching-Liang Lu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Erosive Esophagitis ◽  
Proton Pump Inhibitor Therapy ◽  
Inhibitor Therapy ◽  
Incomplete Response

Proton-pump inhibitor use and hip fractures in men: a population-based case-control study

2014 ◽  
Vol 24 (4) ◽  
pp. 286-290 ◽  
Author(s):  
Annette L. Adams ◽  
Mary Helen Black ◽  
Jian L. Zhang ◽  
Jiaxiao M. Shi ◽  
Steven J. Jacobsen
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Hip Fractures ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Control Study

scholarly journals Proton Pump Inhibitors versus Solitary Lifestyle Modification in Management of Laryngopharyngeal Reflux and Evaluating who is at Risk: Scenario in a Developing Country

2014 ◽  
Vol 7 ◽  
pp. CMENT.S13799 ◽  
Author(s):  
Preetam Chappity ◽  
Rakesh Kumar ◽  
Ramesh C. Deka ◽  
Venkatakarthikeyan Chokkalingam ◽  
Anoop Saraya ◽  
...  
Keyword(s):  
Risk Factors ◽  
At Risk ◽  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Lifestyle Modification ◽  
Laryngopharyngeal Reflux ◽  
Treatment Protocol ◽  
Complete Analysis ◽  
Risk Population ◽  
Early Management

Background Laryngopharyngeal reflux disease can present with a varied symptomatology because of the involvement of multiple sub-sites of the upper aero-digestive tract. It is a very common disease to be encountered in routine practice by both medical and ENT personnel. Its association with multiple pathologies including malignancy warrants an early diagnosis and management. The lack of cost effective and non-invasive tests constitutes a major hurdle in its early management. Objectives 1. To define the “at risk” population, prone to developing laryngopharyngeal reflux. 2. To formulate major and minor risk factors for the clinical diagnosis of patients with laryngopharyngeal reflux. 3. To evaluate the efficacy of lifestyle management alone as a treatment option. 4. To formulate a treatment protocol for the management of patients and to prevent recurrence. Study Design We performed a prospective analysis of 234 patients diagnosed with laryngopharyngeal reflux. Patients were randomized into study and control groups based on the treatment protocol, using a computer generated randomization table and were single blinded to the type of therapy received. A complete analysis of the possible risk factors, symptoms, and signs was performed with statistical analysis. Results and Conclusion The data has helped us define the “at risk” population and formulate the criteria to diagnose cases of laryngopharyngeal reflux, clinically. The results emphasize the non-requirement of invasive or costly investigations for all patients and indicate the probable protocol to be followed prior to considering further investigation. The role of long term proton pump inhibitor treatment along with lifestyle modification in the initial phase of treatment, as mentioned in the literature, was re-confirmed by our study. However, in addition to the initial treatment, the study establishes the need for continuing lifestyle modification further for at least six months after the cessation of proton pump inhibitor therapy to prevent early recurrence of symptoms.

scholarly journals Risk factors for Clostridium difficile infection in HIV-infected patients

2016 ◽  
Vol 4 ◽  
pp. 205031211668429 ◽  
Author(s):  
Hannah Imlay ◽  
Daniel Kaul ◽  
Krishna Rao
Keyword(s):  
Risk Factors ◽  
Clostridium Difficile ◽  
Proton Pump Inhibitor ◽  
Propensity Score ◽  
Confidence Interval ◽  
Proton Pump ◽  
Clostridium Difficile Infection ◽  
Odds Ratio ◽  
Hospital Admissions ◽  
Cd4 Count

Background: Clostridium difficile infection is a healthcare-associated infection resulting in significant morbidity. Although immunosuppression is associated with Clostridium difficile infection acquisition and adverse outcomes, the epidemiology of Clostridium difficile infection in HIV-infected patients has been little studied in the era of antiretroviral therapy. This study identifies the risk factors for acquisition of Clostridium difficile infection in HIV-infected patients. Methods: A retrospective, propensity score–matched case–control study design was employed, with patients selected from our institution’s outpatient HIV clinic. Clostridium difficile infection cases were defined as having positive stool testing plus an appropriate clinical presentation. The propensity score was generated via multiple logistic regression from year of HIV diagnosis, age at first contact, duration of follow-up, gender, and initial CD4 count. Results: The 46 cases included were matched to a total of 180 controls. Prior antibiotic treatment was a significant predictor of Clostridium difficile infection (odds ratio: 13, 95% confidence interval: 3.49–48.8, p < .001) as was number of hospital admissions in the preceding year (odds ratio: 4.02, confidence interval: 1.81–8.94, p < .001). Having both proton pump inhibitor use and CD4 count <200 cells/µL significantly increased odds of Clostridium difficile infection in the multivariable model (odds ratio: 15.17, confidence interval: 1.31–175.9, p = .021). Conclusion: As in the general population, frequent hospitalizations and exposure to antimicrobials are independent predictors of Clostridium difficile infection acquisition in patients with HIV. Additionally, low CD4 count and proton pump inhibitor use are new potentially modifiable variables that can be targeted for prevention of Clostridium difficile infection in future interventional studies.

scholarly journals Proton Pump Inhibitor Therapy Does Not Affect Prognosis of Cirrhosis Patients With Acute Decompensation and Acute-on-Chronic Liver Failure: A Single-Center Prospective Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Shanshan Sun ◽  
Wenyi Ye ◽  
Ruihong Zhao ◽  
Jianhua Hu ◽  
Xuan Zhang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Proton Pump Inhibitor ◽  
Liver Failure ◽  
Proton Pump ◽  
Chronic Liver ◽  
Decompensated Cirrhosis ◽  
Chronic Liver Failure ◽  
Acute Decompensation ◽  
Independent Risk Factors ◽  
The Impact

Background: The aim of this study was to investigate the impact of proton pump inhibitor (PPI) therapy on complications and prognosis in cirrhosis patients with and without acute-on-chronic liver failure (ACLF).Materials and Methods: Cirrhosis patients with acute decompensation (AD) (n = 489) admitted in our center were enrolled in this prospective observational cohort study. According to treatment received, patients were identified as users or nonusers of PPI. Clinical and laboratory data, complications during hospitalization, and overall survival were recorded in all the patients.Results: Of the 489 patients, 299 (61.1%) patients received PPI therapy. The logistic regression analysis showed that age, albumin, history of previous hepatic encephalopathy (HE), and the chronic liver failure-sequential organ failure assessment (CLIF-SOFA) score were independent risk factors for HE in patients with decompensated cirrhosis [odds ratio (OR) = 1.07, 95% CI: 1.03–1.12, p = 0.001; OR = 1.13, 95% CI: 1.04–1.24, p = 0.006; OR = 242.52, 95% CI: 40.17–1464.11, p &lt; 0.001; and OR = 2.89, 95% CI: 2.11–3.96, p &lt; 0.001, respectively]. Previous severe liver injury and previous bacterial infections were independent risk factors for spontaneous bacterial peritonitis (SBP) in patients with decompensated cirrhosis (OR = 3.43, 95% CI: 1.16–10.17, p = 0.026 and OR = 6.47, 95% CI: 2.29–18.29, p &lt; 0.001, respectively). The multivariate Cox proportional hazards regression model showed that the type and dose of the PPI used were not related to 28-day and 90-day mortality in cirrhosis patients with AD or ACLF.Conclusion: PPI use does not appear to increase mortality or the risk of HE and SBP in the hospitalized cirrhosis patients with and without ACLF.

Sign in / Sign up

Export Citation Format

Share Document